Clearing the Air: Nursing Interventions and Pharmacological Management for COPD

Background

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterised by persistent airflow limitation. It encompasses two main forms: chronic bronchitis (inflammation and mucus hypersecretion) and emphysema (destruction of alveolar walls). Patients with COPD experience a range of debilitating symptoms including dyspnoea, chronic cough, sputum production, and exercise intolerance. The disease also predisposes individuals to frequent exacerbations, often triggered by infections or environmental irritants. While part one of this topic typically covers pathophysiology, clinical manifestations, complications, and diagnostic methods, this article focuses on the practical aspects of care: the nursing interventions that support patients during acute and stable phases, and the medication classes used to manage symptoms and prevent disease progression. Understanding these interventions is essential for healthcare providers, caregivers, and individuals living with COPD to optimise respiratory function, maintain oxygen saturation within a safe range, and improve overall quality of life.

Monitoring the Respiratory System

The first and most fundamental intervention for a person with COPD is continuous assessment of the respiratory system. This includes auscultating lung sounds to detect wheezing, crackles, or diminished breath sounds. If the patient has difficulty clearing secretions, nasotracheal suctioning may be required. The need for suction is determined by evaluating the patient's breathing effort and oxygen saturation levels.

Sputum production must also be monitored. Individuals with chronic bronchitis often have ineffective coughs that fail to clear thick mucus. When clinically indicated, a sputum culture may be collected, as these patients are at increased risk of developing pneumonia. Early identification of pathogenic organisms allows for targeted antibiotic therapy.

Oxygen Therapy with a Narrow Target Range

One of the most critical aspects of COPD care is oxygen administration — but not at the levels used for other respiratory conditions. In healthy individuals, the primary stimulus to breathe is an elevated partial pressure of carbon dioxide (hypercapnia). However, in many people with advanced COPD, the respiratory centre becomes less sensitive to carbon dioxide. Instead, their drive to breathe depends on low arterial oxygen levels (hypoxic drive). This physiological adaptation is a consequence of chronic hypercapnia and acidosis.

Therefore, administering high concentrations of oxygen can remove this hypoxic drive, leading to hypoventilation, further retention of carbon dioxide, and potentially life-threatening respiratory failure. The recommended target oxygen saturation range for COPD patients is 88% to 93%. This is lower than the typical 95–100% target for other conditions. Oxygen is usually prescribed at 1–2 litres per minute via nasal cannula. Healthcare providers must monitor oxygen saturation closely and avoid exceeding the target range.

Breathing Retraining: Pursed-Lip and Diaphragmatic Breathing

Two breathing techniques are particularly beneficial for individuals with COPD, especially during episodes of shortness of breath.

Pursed-Lip Breathing

Pursed-lip breathing helps slow down the respiratory rate, prolong exhalation, and keep the airways open longer. The technique involves inhaling slowly through the nose, then exhaling gently through pursed lips — as if blowing out a birthday candle. This method increases oxygen levels, reduces air trapping, and can be more effective than supplemental oxygen alone for relieving acute dyspnoea.

Diaphragmatic (Abdominal) Breathing

Diaphragmatic breathing addresses the mechanical disadvantage caused by hyperinflated lungs. In COPD, the diaphragm becomes flattened and less effective. Patients then rely on accessory muscles (neck, shoulder, and chest wall muscles) to breathe — an inefficient process that consumes large amounts of energy. To retrain the diaphragm, the patient lies on the back with a pillow under the knees. One hand is placed on the chest, the other on the abdomen. The patient inhales deeply using the abdominal muscles (the hand on the chest should move minimally), then exhales through pursed lips while contracting the abdomen. Practised regularly, this technique strengthens the diaphragm, slows breathing, and reduces the energy cost of ventilation. This is particularly important for those with emphysema ("pink puffers") who hyperventilate and experience significant weight loss due to the high caloric demand of breathing.

Airway Clearance and Nebulised Treatments

In hospital settings, respiratory therapists often administer nebulised bronchodilators such as short-acting agents (e.g., albuterol, ipratropium). However, nurses also play a key role in giving scheduled or as-needed inhalers. It is essential to distinguish between short-acting and long-acting bronchodilators. During an acute exacerbation with sudden shortness of breath, a short-acting bronchodilator is used because it acts rapidly to relax airway smooth muscle.

Nutritional and Hydration Support

Caloric and protein needs: Patients with emphysema, in particular, burn a large number of calories due to the increased work of breathing. They require high-calorie, high-protein meals. However, large meals should be avoided. A distended stomach pushes upward against the diaphragm, which is already flattened by hyperinflated lungs, further compromising breathing. Therefore, small, frequent meals (five to six per day) are recommended rather than three large ones.

Hydration: Unless contraindicated by heart failure or renal disease, individuals should drink approximately two to three litres of fluid per day. Adequate hydration keeps mucus secretions thin and easier to expectorate. Thick, tenacious mucus can obstruct airways and increase the risk of infection.

Environmental Protection and Vaccination

People with COPD are highly sensitive to environmental irritants. They should monitor air quality forecasts and avoid going outdoors on days with high pollution, extreme heat, humidity, or very cold temperatures, all of which can trigger exacerbations. Smoking cessation is the single most effective intervention to slow disease progression. Second-hand smoke is equally harmful.

Vaccination is another cornerstone of prevention. Annual influenza vaccination and pneumococcal vaccination (typically every five years) significantly reduce the risk of respiratory infections that can lead to severe exacerbations. Even if an infection occurs, vaccination may lessen symptom severity.

Medication Categories for COPD Management

A systematic approach to remembering the major drug classes used in COPD can be organised using the mnemonic of "COPD" or similar. The following categories are essential knowledge for healthcare providers.

Corticosteroids (Anti-Inflammatory Agents)

Corticosteroids reduce airway inflammation and mucus production. They are particularly useful in chronic bronchitis, where inflamed bronchioles produce excessive mucus. They can be administered orally, intravenously, or via inhalation. Common examples include prednisone, methylprednisolone (Solu-Medrol), and inhaled agents such as budesonide (Pulmicort) or combination products containing a steroid and a long-acting bronchodilator (e.g., budesonide/formoterol).

Key side effects: Easy bruising, fragile skin, hyperglycaemia (even in non-diabetics), increased infection risk due to immunosuppression, and osteoporosis with long-term use.

Important nursing instruction: If a patient is prescribed both a bronchodilator inhaler and a corticosteroid inhaler, the bronchodilator must be used first. The bronchodilator opens the airways, allowing the corticosteroid to penetrate deeper into the lungs. After using a corticosteroid inhaler, the patient should rinse their mouth with water (without swallowing) to prevent oral thrush (candidiasis).

Phosphodiesterase-4 Inhibitors

One drug in this class, roflumilast, is used for patients with chronic bronchitis to reduce the frequency of COPD exacerbations. It is not a bronchodilator.

Side effects to monitor: This medication can cause neuropsychiatric effects, including suicidal ideation. Weight loss is also common. Patients should be instructed to report any changes in mood or thoughts of self-harm, and weight should be monitored regularly.

Methylxanthines

Theophylline is the prototype drug in this category. It acts as a mild bronchodilator by relaxing smooth muscle and is used for long-term management of severe COPD. It is typically given orally.

Critical safety note: Theophylline has a narrow therapeutic range. Desired serum levels are 10–20 mcg/mL. Levels below this are subtherapeutic; levels above increase the risk of toxicity (nausea, vomiting, tachycardia, seizures). Additionally, theophylline can increase digoxin toxicity (requiring monitoring of digoxin levels) and reduce the effectiveness of lithium and phenytoin.

Short-Acting Bronchodilators (Rescue Medications)

These agents rapidly relax bronchial smooth muscle and are used for acute symptom relief or before exertion. They include:

• Short-acting beta-2 agonists (SABA): albuterol
• Short-acting anticholinergics (SAMA): ipratropium (Atrovent)

They are the first-line treatment for sudden shortness of breath.

Long-Acting Bronchodilators (Maintenance Therapy)

These provide sustained bronchodilation and are used on a scheduled basis (once or twice daily). They include:

• Long-acting beta-2 agonists (LABA): salmeterol, formoterol
• Long-acting anticholinergics (LAMA): tiotropium (Spiriva)

Side effects: Beta-2 agonists can cause tachycardia, palpitations, and hypokalaemia (low potassium). Anticholinergics may cause dry mouth, blurred vision, and urinary retention. Patients should be educated about these potential effects.

Expected Outcomes of Consistent Interventions

When nursing interventions and medication management are applied correctly and consistently, individuals with COPD can achieve:

• Improved oxygen saturation maintained within the safe 88–93% range, reducing the risk of hypoxic drive suppression and hypercapnia.
• Decreased frequency and severity of dyspnoea episodes through effective use of pursed-lip and diaphragmatic breathing.
• Enhanced airway clearance via hydration, sputum monitoring, and appropriate suctioning.
• Reduced exacerbation rates from vaccinations, smoking cessation, and avoidance of environmental triggers.
• Better nutritional status with small, high-calorie meals, preventing weight loss and muscle wasting.
• Optimal medication effectiveness by using bronchodilators before corticosteroids and rinsing the mouth after steroid inhalers.
• Minimised adverse drug events through awareness of narrow therapeutic ranges (theophylline), suicide risk (roflumilast), and metabolic effects (corticosteroids).

Conclusion

Managing COPD requires a comprehensive, multidisciplinary approach. Nursing interventions focus on vigilant respiratory monitoring, judicious oxygen therapy (targeting 88–93% saturation), breathing retraining (pursed-lip and diaphragmatic techniques), nutritional and hydration support, environmental protection, and vaccination. The pharmacological regimen includes five main categories: corticosteroids (to reduce inflammation), phosphodiesterase-4 inhibitors (to prevent exacerbations), methylxanthines (with narrow therapeutic windows), short-acting bronchodilators (for acute relief), and long-acting bronchodilators (for maintenance). Understanding the correct order of inhaler use, potential side effects, and drug interactions is essential. When these interventions are applied consistently, individuals with COPD experience better symptom control, fewer hospitalisations, and an improved quality of life. Each person's disease is unique, and care plans must be individualised, but the principles outlined here provide a solid foundation for evidence-based COPD management.